PL3548633T3 - Zastosowanie epigenetycznych interakcji chromosomów w diagnostyce nowotworów - Google Patents

Zastosowanie epigenetycznych interakcji chromosomów w diagnostyce nowotworów

Info

Publication number
PL3548633T3
PL3548633T3 PL17817030.4T PL17817030T PL3548633T3 PL 3548633 T3 PL3548633 T3 PL 3548633T3 PL 17817030 T PL17817030 T PL 17817030T PL 3548633 T3 PL3548633 T3 PL 3548633T3
Authority
PL
Poland
Prior art keywords
chromsomal
epigenetic
interactions
application
cancer diagnostics
Prior art date
Application number
PL17817030.4T
Other languages
English (en)
Polish (pl)
Inventor
Francis Hector GRAND
Aroul Selvam Ramadass
Alexandre Akoulitchev
Ewan HUNTER
Original Assignee
Oxford BioDynamics PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford BioDynamics PLC filed Critical Oxford BioDynamics PLC
Publication of PL3548633T3 publication Critical patent/PL3548633T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6827Hybridisation assays for detection of mutation or polymorphism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00Reaction characterised by the enzymatic activity
    • C12Q2521/30Phosphoric diester hydrolysing, i.e. nuclease
    • C12Q2521/301Endonuclease
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00Reaction characterised by the enzymatic activity
    • C12Q2521/50Other enzymatic activities
    • C12Q2521/501Ligase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2523/00Reactions characterised by treatment of reaction samples
    • C12Q2523/10Characterised by chemical treatment
    • C12Q2523/101Crosslinking agents, e.g. psoralen
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2565/00Nucleic acid analysis characterised by mode or means of detection
    • C12Q2565/50Detection characterised by immobilisation to a surface
    • C12Q2565/501Detection characterised by immobilisation to a surface being an array of oligonucleotides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL17817030.4T 2016-12-01 2017-11-30 Zastosowanie epigenetycznych interakcji chromosomów w diagnostyce nowotworów PL3548633T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662428893P 2016-12-01 2016-12-01
PCT/GB2017/053615 WO2018100381A1 (en) 2016-12-01 2017-11-30 Application of epigenetic chromsomal interactions in cancer diagnostics

Publications (1)

Publication Number Publication Date
PL3548633T3 true PL3548633T3 (pl) 2024-04-02

Family

ID=60702831

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17817030.4T PL3548633T3 (pl) 2016-12-01 2017-11-30 Zastosowanie epigenetycznych interakcji chromosomów w diagnostyce nowotworów

Country Status (12)

Country Link
US (2) US11560597B2 (enExample)
EP (2) EP4357463A3 (enExample)
JP (2) JP2019535295A (enExample)
KR (1) KR102481242B1 (enExample)
CN (1) CN110234769B (enExample)
AU (1) AU2017367245B2 (enExample)
CA (1) CA3045070A1 (enExample)
ES (1) ES2971286T3 (enExample)
MY (1) MY190153A (enExample)
PL (1) PL3548633T3 (enExample)
TW (1) TWI865427B (enExample)
WO (1) WO2018100381A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2626699B (en) * 2019-05-08 2024-11-20 Oxford BioDynamics PLC Chromosome Conformation Markers of Prostate Cancer and Lymphoma
CN118506860B (zh) * 2024-07-18 2024-10-08 广州女娲生命科技有限公司 药物表观遗传安全性评价的检测分析方法及系统

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0611702B1 (pt) * 2005-07-04 2015-05-19 Univ Erasmus Medical Ct Captura e caracterização de cromatina co-localizada (4c)
GB0603251D0 (en) * 2006-02-17 2006-03-29 Isis Innovation DNA conformation
PT2121977T (pt) * 2007-01-11 2017-08-18 Erasmus Univ Medical Center Captura da conformação cromossómica circular (4c)
US20090117076A1 (en) * 2007-11-01 2009-05-07 Chen Lei L Methods For Treating Tumor Cells
GB0810051D0 (en) * 2008-06-02 2008-07-09 Oxford Biodynamics Ltd Method of diagnosis
US9434985B2 (en) * 2008-09-25 2016-09-06 University Of Massachusetts Methods of identifying interactions between genomic loci
US10262103B2 (en) * 2008-11-18 2019-04-16 Raphael LEHRER Individualized cancer treatment
AU2011274642B2 (en) * 2010-07-09 2015-05-21 Cergentis B.V. 3-d genomic region of interest sequencing strategies
CN103547598A (zh) * 2011-02-24 2014-01-29 梅里麦克制药股份有限公司 包含抗-erbb3药剂的联合治疗
WO2012159025A2 (en) * 2011-05-18 2012-11-22 Life Technologies Corporation Chromosome conformation analysis
SG10201610869TA (en) * 2012-06-26 2017-02-27 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalacti
CN102827935B (zh) * 2012-08-29 2013-12-18 北京大学人民医院 定量检测FIP1L1-PDGFRA融合基因mRNA水平的试剂盒
GB201320351D0 (en) * 2013-11-18 2014-01-01 Erasmus Universiteit Medisch Ct Method
US11795496B2 (en) 2015-06-24 2023-10-24 Oxford BioDynamics PLC Epigenetic chromosome interactions
EP3390656B1 (en) 2015-12-14 2020-04-08 The General Hospital Corporation Methods of detecting insulator dysfunction and oncogene activation for screening, diagnosis and treatment of patients in need thereof
GB201608000D0 (en) 2016-05-06 2016-06-22 Oxford Biodynamics Ltd Chromosome detection

Also Published As

Publication number Publication date
EP3548633B1 (en) 2024-01-24
EP4357463A2 (en) 2024-04-24
WO2018100381A1 (en) 2018-06-07
NZ753716A (en) 2024-05-31
US11560597B2 (en) 2023-01-24
KR20190086569A (ko) 2019-07-22
TW201842190A (zh) 2018-12-01
AU2017367245B2 (en) 2020-09-24
AU2017367245A1 (en) 2019-06-06
CN110234769A (zh) 2019-09-13
JP7579003B2 (ja) 2024-11-07
EP4357463A3 (en) 2024-07-17
CA3045070A1 (en) 2018-06-07
JP2019535295A (ja) 2019-12-12
CN110234769B (zh) 2024-06-07
ES2971286T3 (es) 2024-06-04
US20230082230A1 (en) 2023-03-16
US20190338367A1 (en) 2019-11-07
MY190153A (en) 2022-03-31
EP3548633A1 (en) 2019-10-09
KR102481242B1 (ko) 2022-12-23
EP3548633C0 (en) 2024-01-24
TWI865427B (zh) 2024-12-11
JP2023027076A (ja) 2023-03-01

Similar Documents

Publication Publication Date Title
IL281511B (en) A process kit with high electrical conductivity
SG11201606193RA (en) Biomolecule analysis kit and biomolecule analysis method
IL248819A0 (en) Translation during a conversation
IL256025A (en) Methods of diagnosing and treating cancer
SG11201704707PA (en) Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
GB201616912D0 (en) Classification of cancer
GB201420859D0 (en) Tumour analysis
IL263123A (en) Cancer treatments
IL267315A (en) Methods of determining colorectal cancer status in an individual
GB201618200D0 (en) Simultaneous analysis of multiple components in well fluids
GB2543200B (en) Junction-conveyed completion tooling and operations
IL251903A0 (en) Epilimod for use in the treatment of colon cancer
GB201608779D0 (en) Methods and compounds
SG10201913528PA (en) Methods of diagnosing cancer
PL3268337T3 (pl) Sposoby i zestawy do przygotowania kompleksów radionuklidu
GB201608776D0 (en) Methods and compounds
SG10201605375YA (en) Sample holder and sample holder set
SG10201504344VA (en) Component processing
GB201417661D0 (en) Agile Software Development Process And Results
SG11201700893WA (en) Biomolecule analyzer
PT3298165T (pt) Método e kit para diagnóstico de cancro colorretal
GB2546773B (en) Cancer
EP3535421C0 (en) DIAGNOSTIC PROCEDURES
GB201411393D0 (en) Agents and methods for determining colorectal cancer status
GB201611636D0 (en) Diagnostic methods and kits